Company: GHRS
Filing Date: 2025-05-21
Form Type: 6-K
Source: 0001140361-25-019977
Chunk: 0

Company: GH Research PLC
Filing Date: 2025-05-21
Form: 6-K
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

| Form 20-F | ☒ |     | Form 40-F |

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K GH Research PLC (the “Company”) will attend the American Society of Clinical Psychopharmacology (“ASCP”) Annual Meeting, which is scheduled to take place from May 27-30, 2025 in Scottsdale, Arizona (the “Congress”). The Company will present posters during the Congress. A copy of the poster to be delivered in conjunction with the Pharmaceutical Pipeline Presentation session, presented by Michael E. Thase, is attached hereto as Exhibit 99.1. A copy of the poster to be presented by Wiesław J. Cubała to be delivered during Poster Session II is attached hereto as Exhibit 99.2. A copy of the poster to be presented by Claus Bo Svendsen to be delivered during Poster Session II is attached hereto as Exhibit 99.3. 1 EXHIBIT INDEX

| Exhibit No. | Description                                                                                                                                                                                |
| 99.1        | Poster presented by Michael E. Thase with Title: Safety and Efficacy of GH001 in Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomized Controlled Trial        |
| 99.2        | Poster presented by Wiesław J. Cubała, with Title: Safety and Tolerability of GH001 in Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomized, Controlled Trial |
| 99.3        | Poster presented by Claus Bo Svendsen with Title: Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients With Postpartum Depression                               |

2 SIGNATURE Pursuant to the requirements of